Archaeal lipid mucosal vaccine adjuvant and delivery system

Expert Review of Vaccines

Volumn 9, Issue 4, 2010, Pages 431-440

  Patel, Girishchandra B ^a   Chen, Wangxue ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Adjuvant; Archaeal lipid; Intranasal; Mucosal; Vaccine

Indexed keywords

ARCHAEAL POLAR LIPID; ARCHAEOL; ARCHAEOSOME; BACTERIAL VACCINE; BACTERIAL VECTOR; CALDARCHAEOL; CATION; CD8 ANTIGEN; CHOLERA VACCINE; DIPHTHERIA VACCINE; FRANCISELLA TULARENSIS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INFLUENZA VACCINE; LIPID; LIPOSOME; LIVE VACCINE; MEMBRANE ANTIGEN; O ANTIGEN; OVALBUMIN; PHOSPHORYL LIPID A; PNEUMOCOCCAL SURFACE ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARCHAEAL LIPID MUCOSAL VACCINE ADJUVANT AND DELIVERY SYSTEM; ARCHAEBACTERIUM; BILE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULARY; DRUG SAFETY; DRUG STORAGE; FECES; FRANCISELLA TULARENSIS; HOST; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; LIPID PEROXIDATION; MEMBRANE VESICLE; MUCOSAL IMMUNITY; NEISSERIA MENINGITIDIS; NOSE MUCOSA; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEOLIPOSOME; REVIEW; SERUM; THERMOSTABILITY; ULTRASOUND; VAGINA MUCOSA; VIRUS LIKE AGENT; ANIMAL; ARCHAEON; IMMUNOLOGY; INTESTINE MUCOSA; MOUTH MUCOSA; PROCEDURES; TRENDS; ULTRASTRUCTURE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ARCHAEA; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; LIPIDS; MOUTH MUCOSA; NASAL MUCOSA;

EID: 77950613459     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.34     Document Type: Review

References (74)

1. Jakobsen H, Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria - new potentials for conjugate vaccines? Scand. J. Immunol. 58(2), 119-128 (2003).
2. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25(30), 5467-5484 (2007).
3. Mestecky J, Moldoveanu Z, Michalek SM et al. Current opinions for vaccine delivery systems by mucosal routes. J. Control. Release 48, 243-257 (1997).
4. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006).
5. Singh M, O'Hagan DT. Recent advances in vaccine adjuvants. Pharm. Res. 19(6), 715-728 (2002).
6. Davis SS. Nasal vaccines. Adv. Drug Deliv. Rev. 51(1-3), 21-42 (2001).
7. Mestecky J, Nguyen H, Czerkinsky C, Kiyono H. Oral immunization: an update. Curr. Opin. Gastroenterol. 24(6), 713-719 (2008).
8. De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv. Drug Deliv. Rev. 58(1), 52-67 (2006).
9. Goyal AK, Khatri K, Mishra N, Vyas SP. New patents on mucosal delivery of vaccines. Expert Opin. Ther. Pat. 18(11), 1271-1288 (2008).
10. Mann JF, Acevedo R, Campo JD, Perez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev. Vaccines 8(1), 103-112 (2009).
11. Mitragotri S. Immunization without needles. Nat. Rev. Immunol. 5(12), 905-916 (2005).
12. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 23(15), 1804-1813 (2005).
13. Holmgren J, Czerkinsky C, Eriksson K, Harandi AM. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21(Suppl. 2), S89-S95 (2003).
14. Yuki Y, Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. 13(5), 293-310 (2003).
15. Fujihashi K, Kiyono H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol. 30(7), 334-343 (2009).
16. Ryan EJ, Daly LM, Mills KHG. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol. 19(8), 293-304 (2001).
17. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 58(1), 68-89 (2006).
18. Lemoine D, Francotte M, Preat V. Nasal vaccines. From fundamental concepts to vaccine development. STP Pharma Sci. 8(1), 5-18 (1998).
19. Perrie Y, Kirby D, Bramwell VW, Mohammed AR. Recent developments in particulate-based vaccines. Recent Pat. Drug Deliv. Formul. 1(2), 117-129 (2007).
20. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14(2), 430-445 (2001).
21. Demberg T, Robert-Guroff M. Mucosal immunity and protection against HIV/ SIV infection: strategies and challenges for vaccine design. Int. Rev. Immunol. 28(1), 20-48 (2009).
22. Vajdy M, Srivastava I, Polo J, Donnelly J, O'Hagan D, Singh M. Mucosal adjuvants and delivery systems for protein-, DNA-and RNA-based vaccines. Immunol. Cell Biol. 82(6), 617-627 (2004).
23. Baumann U. Mucosal vaccination against bacterial respiratory infections. Expert Rev. Vaccines 7(8), 1257-1276 (2008).
24. Kemble G, Greenberg H. Novel generations of influenza vaccines. Vaccine 21(16), 1789-1795 (2003).
25. Oliveira ML, Areas AP, Ho PL. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev. Vaccines 6(3), 419-429 (2007).
26. Vyas SP, Gupta PN. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines 6(3), 401-418 (2007).
27. Christensen D, Korsholm KS, Rosenkrands I, Lindenstrom T, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 6(5), 785-796 (2007).
28. Giri PK, Khuller GK. Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev. Vaccines 7(9), 1341-1356 (2008).
29. Perez O, Lastre M, Cabrera O et al. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand. J. Immunol. 66(2-3), 271-277 (2007).
30. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 30(1), 23-32 (2009).
31. O'Hagan DT, Rappuoli R. Novel approaches to vaccine delivery. Pharm. Res. 21(9), 1519-1530 (2004).
32. Garcon N, Chomez P, Van Mechelen M. Glaxosmithkline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6(5), 723-739 (2007).
33. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 25(19), 3752-3762 (2007).
34. Byrd W, Cassels FJ. Intranasal immunization of BALB/c mice with enterotoxigenic Escherichia coli colonization factor CS6 encapsulated in biodegradable poly(dl-lactide-co-glycolide) microspheres. Vaccine 24(9), 1359-1366 (2006).
35. Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines. Expert Rev. Vaccines 6(5), 761-772 (2007).
36. Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 80(10), 4962-4970 (2006).
37. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364(2), 272-280 (2008).
38. Patel GB, Ponce A, Zhou H, Chen W. Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice. Int. J. Toxicol. 27, 329-339 (2008).
39. Patel GB, Ponce A, Zhou H, Chen W. Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice. J. Liposome Res. 18(2), 127-143 (2008).
40. Patel GB, Zhou H, Ponce A, Chen W. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine 25(51), 8622-8636 (2007).
41. Kates M. Archaebacterial lipids: structure, biosynthesis and function. Biochem. Soc. Symp. 58, 51-72 (1992).
42. Sprott GD. Structures of archaebacterial membrane lipids. J. Bioenerg. Biomembr. 24(6), 555-566 (1992).
43. Patel GB, Sprott GD. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit. Rev. Biotechnol. 19(4), 317-357 (1999).
44. Krishnan L, Sprott GD. Archaeosome adjuvants: immunological capabilities and mechanism(s) of action. Vaccine 26(17), 2043-2055 (2008).
45. Koga Y, Morii H. Recent advances in structural research on ether lipids from archaea including comparative and physiological aspects. Biosci. Biotechnol. Biochem. 69(11), 2019-2034 (2005).
46. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4(2), 145-160 (2005).
47. Sprott GD, Dicaire CJ, Fleming LP, Patel GB. Stability of liposomes prepared from archaeobacterial lipids and phosphatidylcholine mixtures. Cell Mater. 6, 143-155 (1996).
48. Patel GB, Chen W. Archaeosome immunostimulatory vaccine delivery system. Curr. Drug Deliv. 2(4), 407-421 (2005).
49. Choquet CG, Patel GB, Beveridge TJ, Sprott GD. Stability of pressure-extruded liposomes made from archaeobacterial ether lipids. Appl. Microbiol. Biotechnol. 42(2-3), 375-384 (1994). (Pubitemid 24373922)
50. Patel GB, Agnew BJ, Deschatelets L, Fleming LP, Sprott GD. In vitro assessment of archaeosome stability for developing oral delivery systems. Int. J. Pharm. 194(1), 39-49 (2000).
51. Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help. J. Immunol. 165(9), 5177-5185 (2000).
52. Sprott GD, Tolson DL, Patel GB. Archaeosomes as novel antigen delivery systems. FEMS Microbiol. Lett. 154(1), 17-22 (1997).
53. Conlan JW, Krishnan L, Willick GE, Patel GB, Sprott GD. Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, Listeria monocytogenes. Vaccine 19(25-26), 3509-3517 (2001). (Pubitemid 32710303)
54. Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res. 63(10), 2526-2534 (2003). (Pubitemid 36605193)
55. Gould-Fogerite S, Mannino RJ. Mucosal and systemic immunization using cochleate and liposome vaccines. J. Liposome Res. 6, 357-379 (1996). (Pubitemid 26167305)
56. Gould-Fogerite S, Mannino RJ. Cochleates for induction of mucosal and systemic immune responses. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. O'Hagan DT (Ed.). Humana Press, Inc., NJ, USA, 179-196 (2000).
57. Papahadjopoulos D, Vail WJ, Jacobson K, Poste G. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta 394(3), 483-491 (1975).
58. Gherardi MM, Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J. Gen. Virol. 86(Pt 11), 2925-2936 (2005). (Pubitemid 41555556)
59. Haneberg B, Herland Berstad AK, Holst J. Bacteria-derived particles as adjuvants for non-replicating nasal vaccines. Adv. Drug Deliv. Rev. 51(1-3), 143-147 (2001). (Pubitemid 32763078)
60. Baca-Estrada ME, Foldvari M, Snider M et al. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 18, 2203-2211 (2000). (Pubitemid 30136359)
61. Harokopakis E, Hajishengallis G, Michalek SM. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect. Immun. 66(9), 4299-4304 (1998). (Pubitemid 28402705)
62. Kersten GF, Crommelin DJ. Liposomes and ISCOMS as vaccine formulations. Biochim. Biophys. Acta 1241(2), 117-138 (1995).
63. Vadolas J, Davies JK, Wright PJ, Strugnell RA. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur. J. Immunol. 25(4), 969-975 (1995).
64. Gould-Fogerite S, Kheiri MT, Zhang F et al. Targeting immune response induction with cochleate and liposome-based vaccines. Adv. Drug Deliv. Rev. 32(3), 273-287 (1998). (Pubitemid 28267413)
65. Betageri GV, Jenkins SA, Parsons DL. Liposome Drug Delivery Systems. Technomic Publishing Co., Inc., PA, USA (1993).
66. Ausborn M, Nuhn P, Schreier HJ. Stabilization of liposomes by freeze-thaw and lyophilization techniques: problems and opportunities. Eur. J. Pharm. Biopharm. 38, 133-139 (1992).
67. Bracho G, Lastre M, Campo J et al. Proteoliposome derived cochleate as novel adjuvant. Vaccine 24(Suppl. 2), 30-31 (2006).
68. Perez O, Bracho G, Lastre M et al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol. Cell Biol. 82(6), 603-610 (2004). (Pubitemid 39563961)
69. Sanders MT, Deliyannis G, Pearse MJ, McNamara MK, Brown LE. Single dose intranasal immunization with ISCOMATRIX™ vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine 27(18), 2475-2482 (2009).
70. Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug Deliv. Rev. 51(1-3), 149-159 (2001). (Pubitemid 32763079)
71. Blocher D, Six L, Gutermann R, Henkel B, Ring K. Physicochemical characterization of tetraether lipids from Thermoplasma acidophilum. Calorimetric studies on miscibility with diether lipids carrying branched or unbranched alkyl chains. Biochim. Biophys. Acta 818, 333-342 (1985). (Pubitemid 15019092)
72. Chen JS, Barton PG, Brown D, Kates M. Osmometric and microscopic studies on bilayers of polar lipids from the extreme halophile, Halobacterium cutirubrum. Biochim. Biophys. Acta 352(2), 202-217 (1974).
73. Szoka F Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu. Rev. Biophys. Bioeng. 9, 467-508 (1980).
74. Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect. Immun. 68(1), 54-63 (2000). (Pubitemid 30016677)